Adequate hematologic function
Adequate hematologic function
Participants with hematologic lymphoma
Adequate hematologic and organ function
Adequate hematologic function within  days prior to study registration defined as meeting all of the following criteria:
Adequate hematologic and organ function within  days before the first study treatment
The patient has adequate baseline hematologic function, as demonstrated by the following:
Adequate hematologic parameters unless clearly due to the disease under study
Adequate hematologic status
The participant has adequate hematologic, organ, and coagulation function ? weeks ( days) prior to first dose of study drug:
Have adequate hematologic, organ and coagulation function within  weeks ( days) prior to enrollment.
Have adequate hematologic function within  days prior to study treatment, defined as meeting all of the following criteria:
Adequate organ function, hematologic status, coagulation status, kidney function, and liver function as follows:
Any history of or current hematologic malignancy
Adequate hematologic and organ function
Concurrent hematologic or non-hematologic malignancy requiring treatment
Adequate hematologic function
Hematologic malignancy
Patients with history of hematologic malignancy
Adequate hematologic parameters without ongoing transfusional support:
Hematologic (BM Function):
Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma and secondary amyloidosis)
Patients with a hematologic malignancy or solid tumor
Patients with more than one malignancy (hematologic or solid tumor) are eligible
Any history of or current hematologic malignancy
Adequate hematologic parameters without ongoing transfusional support:
Treatment for non-hematologic malignancy greater than  months prior to enrollment is acceptable
Adequate hematologic function (unless abnormalities are related to NHL), defined as follows:
Hematologic or lymphoid malignancy
Other hematologic/biochemistry requirements, as per protocol
Adequate non-hematologic organ system function, defined by:
Adequate hematologic parameters without ongoing transfusional support:
Patients receiving any other standard or investigational treatment for their hematologic malignancy
Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma or secondary amyloidosis)
Hematologic (BM Function):
Adequate kidney and hematologic function assessed from baseline laboratory data
Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within  days before randomization.
Have adequate hematologic function.
Adequate hematologic function:
Adequate hematologic function
Adequate hematologic and organ function within  days prior to initiation of study treatment
Adequate hematologic function
Adequate hematologic function
Hematologic and Non-hematologic exclusion criteria before start of therapy.
Adequate hematologic function:
Adequate hematologic and organ function within  days before the first study treatment
Adequate hematologic function
Adequate baseline hematologic function, as demonstrated by the following:
Adequate hematologic status
Adequate hematologic function:
Adequate hematologic function within  days prior to registration for protocol therapy defined as meeting all of the following criteria:
Have adequate organ and hematologic function, as determined by:
Adequate hematologic function as defined by:
Patients must have adequate hematologic and organ function.
Splenomegaly or history of proliferative hematologic disease
Adequate hematologic function
Have adequate hematologic function, defined as meeting all of the following criteria:
Adequate hematologic function within protocol-defined parameters.
Adequate hematologic function Arm A (except for CLL subjects with significant BM involvement by biopsy) must meet the following criteria:
Acceptable hematologic and organ function
Subject has the following laboratory parameters at screening: Adequate hematologic function including:
For the hematologic malignancy patients, blood count values cited above do not apply.
Adequate hematologic function, as defined by the following criteria:
Adequate hematologic function.
Adequate hematologic and organ function within  days before the first study treatment
Adequate hematologic function:
Adequate hematologic function defined by:
Adequate hematologic function
Antecedent hematologic disease
Hematologic:
Receiving any other standard treatment for their hematologic malignancy.
Hematologic function, as follows:
Hematologic status:
Adequate hematologic and organ function within  days prior to treatment initiation
Adequate hematologic function.
A diagnosis of any hematologic or solid malignancy
Patients with hematologic malignancy receiving care (chemotherapy, immunotherapy, targeted agents, bone marrow transplant, or other) for their hematologic malignancy at the Ohio State University
Hematologic malignancy
Adequate hematologic function as indicated by:
Patients diagnosed with a hematologic malignancy
